

Michigan Pharmacy and Therapeutics Committee  
Meeting of June 3, 2008  
Kellogg Center, Michigan State University, East Lansing MI,  
DRAFT DRAFT Minutes DRAFT DRAFT

Introduction and approval of minutes of March 4, 2008 meeting

Dr. Nedd introduced G. Robert Young, PharmD, a new member of the Drug Utilization Review Board. Committee members present included Drs. Inman, Bradley, Van Loo, Nedd, Perri, Dillon, Rogers, Arend, Dake, Dorfman. State staff present included Dr. Eggleston, Dr. Nina Matterella, Jacqueline Coleman, Sean Bodell, Heather Slawinski, Cynthia Green-Edwards. Annette Paul, RPh, from First health also participated.

The Minutes of the March 4, 2008 Meeting were approved.

New Drugs and Line Extensions:

Following review and discussion, the Committee recommended to the Department the following:

**Somatuline:** Add to the Michigan Pharmaceutical Product List (MPPL)

**Azor:** Add to the MPPL and to the Preferred Drug List (PDL) class “Antihypertensive Combinations: ARB-CCB” without prior authorization (PA)

**Flector patch;** Add to the MPPL with PA

**Iquix:** Add to the MPPL and to the PDL class “Ophthalmic Fluoroquinolones” with PA

**Veregen:** Add to the MPPL with PA

**Combigan:** Add to the MPPL and to the PDL as a class for “Combination Alpha 2 Adrenergic-Beta Blocker” in the Ophthalmics Section without PA

**Arcalyst:** Add to the MPPL with PA

**Bystolic:** Add to the MPPL and to the PDL class “Beta Blockers” without PA; review utilization after six months to study the trends in its use

**Renvela:** Add to the MPPL and to the PDL class “Electrolyte Depleters” without PA

**Simcor:** Add to the MPPL and to the PDL class “Lipotropics: Statins” with an electronic edit that would allow processing at point of service for any beneficiary who has a history of being on any statin and/ or niacin product; for other beneficiaries, PA would be required

**Adoxa CK kit:** Add to the MPPL with PA, as doxycycline has a State Maximum Allowable Cost on the MPPL

**Atralin gel:** Add to the MPPL with the same parameters as the other tretinoin

**Solonpas:** Non cover this product

**Totect:** physician administered service

**Doribax** physician administered service

Announcement of New PDL Classes

Based on a recommendation from the National Medicaid Pooling Initiative, the Department will add two new drug classes to the PDL:

Growth Hormones will be added to the Miscellaneous Category

All products will be listed equally with a clinical edit requiring patient specific authorization as is currently the case  
Ulcerative Colitis drugs (oral) will be added to the Gastrointestinal Category  
At this time, Asacol, Pentasa, Sulfasalazine will be available without PA  
Azulfidine DR, Balsalazide, Colazal, Dipentum and Lialda will require PA  
The Committee had been surveyed on these two classes and had no objections to these classifications  
Both these classes will be reviewed again clinically at the September meeting

#### Review of PDL Classes

Following review and discussion the Committee recommended to the Department the following:

##### **Antibiotics-Anti-infectives**

###### Antifungals-Onychomycosis

No change to the current classification of drug products

List Grifulvin V and Gris Peg in addition to griseofulvin for clarification

###### Antifungals-Oral

No change to the current classification of drug products

###### Antivirals-Herpes

No change to the current classification of drug products

###### Antivirals-Influenza

No change to the current classification of drug products

###### Cephalosporins 1<sup>st</sup> Generation

No change to the current classification of drug products

###### Cephalosporins 2<sup>nd</sup> Generation

Remove Cefzil suspension and replace with cefprozil suspension

No change to the current classification of the other drug products

###### Cephalosporins 3<sup>rd</sup> Generation

No change to the current classification of drug products

###### Hepatitis C

Remove prior authorization from Peg Intron

No change to the current classification of the other drug products

###### Ketolides

No change to the current classification of the drug product

###### Macrolides

No change to the current classification of drug products

###### Quinolones

No change to the current classification of drug products

###### Otic Quinolones

Add ofloxacin otic without prior authorization

Change Floxin Otic to requiring prior authorization

In addition, the group discussed Zyvox (linezolid) an antibiotic not in one of the existing PDL classes, and currently without restrictions on the MPPL. The Committee recommended adding a PDL class, "Oxalodinones" and listing Zyvox as available without PA. Utilization of it should be monitored by the Department

## **Asthma-Allergy**

### Inhaled Anticholinergics

No change to the current classification of the drug products

### Antihistamines-2<sup>nd</sup> Generation

Change fexofenadine to requiring prior authorization

Remove prior authorization from cetirizine

Other drug products to maintain current classification

### Beta Adrenergics-Short Acting

No change to the current classification of the drug products

### Beta Adrenergics-Long Acting

No change to the current classification of the drug products

### Beta Adrenergics for Nebulizers

No change to the current classification of the drug products

### Beta Adrenergic/Corticosteroid Inhaler Combinations

No change to the current classification of the drug products

### Inhaled Glucocorticoids

Create a step edit for Pulmicort Flexihaler; if a beneficiary has a history of use of pulmicort nebulizer solution and/ or Symbicort, then allow processing at point of service; for beneficiaries just being started on the Pulmicort flexihaler, that would now require prior authorization

No change to the current classification of the other drug products

### Leukotriene Inhibitors

No change to the current classification of the drug products

### Nasal Steroids

No change to the current classification of the drug products

### Public Comment

The following persons commented:

L. Goetz, PharmD, P&G, Actonel, Asacol

Dr. Alzohali, Takeda, Actos

R. Pannone, PharmD, Amgen, Enbrel

G. Katz,MD, Alcon, Vigamox, Travatan, Patanol

J. Baker, PharmD, Astellas, Vesicare, Protopic

T. Edwards,PharmD, GSK, Treximet

D. Smith, MD, Eli Lilly, insulin products

G. Anderson, PhD, AstraZeneca, Nexium

M. Stevens, PharmD, TAP, Prevacid  
S. Scarbrough, Biogen Idec, Avonex  
S. Robinson, RPh, Amylin, Byetta, Symlin  
P. Sardo, PharmD, Abbott, Simcor, Humira  
Dr. Lavery, Dr. Rosenberg, Allergan, Combigan, Sanctura  
D. Iacobellis, PharmD, Pfizer, Detrol LA  
M. Landers, Jr, PharmD, Shire, Lialda  
S. Servera, MD, Novo Nordisk, analog insulins and FlexPen

Dr. Nedd acknowledged the time served and the wonderful contributions Dr. Van Loo has made to the P and T Committee

Next Meeting: Tuesday, September 9, 2008